Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vivos Therapeutics ( (VVOS) ) has shared an announcement.
On January 15, 2026, Vivos Therapeutics, Inc. entered into an unsecured, non‑interest‑bearing (absent default) convertible promissory note of up to $5.5 million in maximum principal with V-Co Investors 3 LLC, an affiliate of existing private equity investor New Seneca Partners Inc., to provide bridge funding ahead of a proposed equity financing of the same size expected to close by February 16, 2026. The note, which includes a 10% original issuance discount as a financing fee, provided an initial $900,000 advance on January 15, 2026, will automatically convert dollar-for-dollar into the securities issued in the contemplated equity raise if that financing occurs before the outside date, and was placed as an unregistered private offering under U.S. securities law, underscoring Vivos’s near-term funding needs and further aligning the company with an existing strategic investor while diluting future equity rather than adding interest-bearing debt.
The most recent analyst rating on (VVOS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.
Spark’s Take on VVOS Stock
According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.
VVOS scores low primarily due to persistent losses, worsening cash burn, and a pressured balance sheet (shrinking equity and higher leverage), which raise financing risk. Technicals also remain bearish with the stock trading below key moving averages. Offsetting these negatives, the earnings call showed meaningful revenue acceleration tied to the new acquisition/affiliation strategy, but profitability and cash flow have not yet followed.
To see Spark’s full report on VVOS stock, click here.
More about Vivos Therapeutics
Vivos Therapeutics, Inc. operates in the healthcare sector; based on the filing, it is a publicly traded company that raises capital through private placements and equity financings, and counts private equity firms such as New Seneca Partners Inc. among its existing investors and advisors.
Average Trading Volume: 144,767
Technical Sentiment Signal: Strong Sell
Current Market Cap: $18.79M
See more data about VVOS stock on TipRanks’ Stock Analysis page.